CARDIOVASCULAR EFFECT OF CINNAMON CAPSULES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND HYPERTENSION

INTERVENTION: Intervention1: Cinnamon capsule: After qualitative and phytochemical analysis cinnamon extract will be converted into the capsule as per the standard recommended doses used in previous studies. Cinnamon extract capsule of 1000mg or 2000mg per day to be taken for a period of 12 weeks for the intervention group and a similar Placebo for the control group. This is in addition to standard therapy. Along with this, both groups continue to receive oral OHA and antihypertensive agents as standard therapy as per ADA and ACC guidelines. Control Intervention1: Placebo: Similar looking placebo capsule will be given to the comparator for 12 weeks. CONDITION: Health Condition 1: I10‐ Essential (primary) hypertension Health Condition 2: E119‐ Type 2 diabetes mellitus without complications PRIMARY OUTCOME: At the end of 12 weeks see the change in blood pressure, hs‐CRP level, and Plasma homocysteine level.Timepoint: At the beginning of the study both groups will be analyzed for baseline Systolic and Diastolic Blood Pressure, CRPH, and plasma homocysteine level. Patients will be asked for follow‐up after 12 weeks of treatment and repeat Systolic and Diastolic Blood Pressure, CRPH, Plasma homocysteine level will be measured SECONDARY OUTCOME: â?¢ AT the end of 12 weeks to see a change in HOMA‐IR, glycemic control in the study group with the control group on standard therapy. ; ; Timepoint: At the beginning of the study, both groups will be analyzed for baseline HOMA‐IR. Patients will be asked for follow‐up after 12 weeks of treatment and repeat HOMA‐IR level will be measured. INCLUSION CRITERIA: Inclusion criteria Age 30‐60 years Patients with type 2 diabetes mellitus based on ADA criteria. Patient with Hypertension Patients taking Oral hypoglycemic agents. HbA1C: > 7